3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Uterine Cervical Neoplasms
8
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Ovarian Neoplasms
2
Melanoma
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Recurrence
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Locally Advanced Cervical Cancer
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Merkel Cell
1
Carcinoid Tumor
1
Breast Neoplasms
1
Interventions
aldesleukin
2
Trastuzumab
2
zimberelimab
1
trametinib
1
tipifarnib
1
sargramostim
1
fludarabine
1
dabrafenib
1
cobimetinib
1
Vemurafenib
1
Nivolumab
1
Ipilimumab
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Carcinoma, Anaplastic
×
zimberelimab
×
Gynecologic
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled